A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Atypical antipsychotics have similar clinical efficacy in the treatment of schizophrenia; variability in their tolerability represents the discerning factor in treatment choices. Sertindole has a relatively good tolerability profile that favours long-term patient adherence and, therefore, is associated with lower rates of relapse and rehospitalization.

AIM: A model was developed to compare the cost-effectiveness of a 5-year treatment strategy starting with sertindole versus olanzapine, risperidone, aripiprazole or the typical antipsychotic agent, haloperidol.

METHODS: The model was based on published trials and local clinical practice, and considered costs from the perspective of the Swedish National Health Insurance Board.

RESULTS: All atypical agents were clinically superior and more cost-effective than haloperidol with a cost per quality-adjusted life year gained of approximately 490,000 Swedish kroner. Sertindole was associated with the lowest direct and indirect medical costs, driven by its tolerability profile.

CONCLUSIONS: Sertindole represents a useful alternative to the current treatment options available in Sweden.

CLINICAL IMPLICATIONS: The relatively good tolerability profile of sertindole translates into lower costs of schizophrenia management, primarily driven by substantially lower direct and indirect costs. Sertindole appears to be a clinically and cost-effective alternative in the management of patients with schizophrenia in Sweden.

Details

Authors
  • Eva Lindström
  • Jonas Eberhard
  • Björn M Fors
  • Karina Hansen
  • Christophe Sapin
External organisations
  • Uppsala University Hospital
  • King's College London
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Psychiatry

Keywords

  • Adult, Antipsychotic Agents, Aripiprazole, Benzodiazepines, Cost-Benefit Analysis, Economics, Pharmaceutical, Female, Haloperidol, Humans, Imidazoles, Indoles, Male, Models, Economic, National Health Programs, Piperazines, Quinolones, Risperidone, Schizophrenia, Sweden
Original languageEnglish
Pages (from-to)403-13
Number of pages11
JournalNordic Journal of Psychiatry
Volume65
Issue number6
Publication statusPublished - 2011 Dec
Publication categoryResearch
Peer-reviewedYes
Externally publishedYes